Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
241. |
ECCT/13/05/01 | Use of the Shang Ring device in all four childhood age groups in the African population |
Principal Investigator(s) 1. Quentin David Awori Site(s) in Kenya Homa Bay District Hospital |
View |
242. |
ECCT/13/04/08 | Switching At Low HIV-1 RNA Into Fixed Dose Combinations SALIF Protocol Number: TMC278IFD3002 Amendment INT-1 |
Principal Investigator(s) 1. Edwin Onyango WERE 2. Milton Tony OMONDI 3. Gina OUATTARA 4. Gaudensia Nzembi MUTUA 5. Reena SHAH Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. KEMRI/Walter-Reed Project Kombewa (Kisumu county) 3. Partners in Prevention (Uasin Gishu county) 4. Kenya AIDS Vaccine Initiative - KNH (Nairobi City county) 5. Kenya AIDS Vaccine Initiative - Kangemi (Nairobi City county) |
View |
243. |
ECCT/20/04/02 | PROSYNK Study A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya. |
Principal Investigator(s) 1. Stephen Allen Site(s) in Kenya 1. Homa Bay County Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) 3. Migori County Referral Hospital (Migori county) 4. Rongo Sub-County Hospital (Migori county) 5. Rachuonyo Sub County Hospital (Homa Bay county) 6. Kendu Bay Sub-County Hospital (Homa Bay county) 7. Ahero County Hospital (Kisumu county) 8. Rabuor Sub-County Hospital (Kisumu county) 9. Akala Sub-County Hospital (Siaya county) 10. Bondo Sub-County Hospital (Siaya county) |
View |
244. |
ECCT/17/03/01 | The POWER cohort A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women |
Principal Investigator(s) 1. Dr. Stella Njuguna Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county) |
View |
245. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
View |